Demographic and clinical characteristics of allogeneic SCT patients who were given bendamustine, fludarabine, and rituximab
| Characteristic . | Value . |
|---|---|
| No. of patients | 56 |
| Median age, y (range) | 59 (30-70) |
| Age ≥60 y | 24 (43) |
| Sex | |
| Male | 35 (63) |
| Female | 21 (38) |
| LDH above normal | 13 (23) |
| Median β-2 microglobulin (range) | 2.2 (1.4-5.0) |
| PET+, no./total (%) | 14/51 (27) |
| Median no. of prior chemotherapies (range) | 3 (1-7) |
| Prior autologous transplantation | 7 (13) |
| Histologic types | |
| Follicular lymphoma | 13 (23) |
| Mantle cell lymphoma | 16 (29) |
| Diffuse large B-cell lymphoma | 9 (16) |
| Peripheral T-cell lymphoma | 3 (5) |
| CLL/Richter | 13/2 (23/4) |
| IgHV unmutated | 10/11(91) |
| ZAP70 positive | 7/11(64) |
| 17p deletion (FISH) | 5 (33) |
| Complex cytogenetic | 5 (33) |
| Median time from diagnosis to transplantation, y (range) | 4.3 (0.4-19.2) |
| Disease status at transplantation | |
| CR | 25 (45) |
| PR | 25 (45) |
| Chemorefractory | 6 (10) |
| Donor | |
| Matched related | 30 (54) |
| Matched unrelated | 26 (46) |
| Stem cell source | |
| Peripheral blood/marrow | 52/4 (93/7) |
| ABO-mismatched recipient/donor | 27 (48) |
| Cytomegalovirus status | |
| R+/D+ | 22 (39) |
| R+/D− | 17 (30) |
| R−/D+ | 8 (14) |
| R−/D− | 9 (16) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 56 |
| Median age, y (range) | 59 (30-70) |
| Age ≥60 y | 24 (43) |
| Sex | |
| Male | 35 (63) |
| Female | 21 (38) |
| LDH above normal | 13 (23) |
| Median β-2 microglobulin (range) | 2.2 (1.4-5.0) |
| PET+, no./total (%) | 14/51 (27) |
| Median no. of prior chemotherapies (range) | 3 (1-7) |
| Prior autologous transplantation | 7 (13) |
| Histologic types | |
| Follicular lymphoma | 13 (23) |
| Mantle cell lymphoma | 16 (29) |
| Diffuse large B-cell lymphoma | 9 (16) |
| Peripheral T-cell lymphoma | 3 (5) |
| CLL/Richter | 13/2 (23/4) |
| IgHV unmutated | 10/11(91) |
| ZAP70 positive | 7/11(64) |
| 17p deletion (FISH) | 5 (33) |
| Complex cytogenetic | 5 (33) |
| Median time from diagnosis to transplantation, y (range) | 4.3 (0.4-19.2) |
| Disease status at transplantation | |
| CR | 25 (45) |
| PR | 25 (45) |
| Chemorefractory | 6 (10) |
| Donor | |
| Matched related | 30 (54) |
| Matched unrelated | 26 (46) |
| Stem cell source | |
| Peripheral blood/marrow | 52/4 (93/7) |
| ABO-mismatched recipient/donor | 27 (48) |
| Cytomegalovirus status | |
| R+/D+ | 22 (39) |
| R+/D− | 17 (30) |
| R−/D+ | 8 (14) |
| R−/D− | 9 (16) |
Data are n (%) unless otherwise indicated.
FISH, fluorescence in situ hybridization; PET, positron emission tomography.